STORIES / This Insulin Pump Just Got Cleared for Type 2. Here's What That Means. Sequel's twiist AID system, already on the market for type 1, is cleared for insulin-treated type 2 adults. A pivotal trial reported A1c and time-in-range gains. It's Rx only.
By WellWham Editorial October 16, 2026 3 min read
THE WHAM ⚡
The story in 10 seconds: Sequel Med Tech’s twiist automated insulin pump, already on the market for type 1, just got FDA clearance for adults 18+ with insulin-treated type 2 diabetes. Prescribing can start now in the U.S., through pharmacies. If you’ve lived with insulin-treated type 2, you know the drill. Fingersticks or a CGM, dose math, and a lot of “wait, did I already take that?” Automated pumps have mostly been a type 1 story. That just changed. On October 16, Sequel Med Tech said the FDA cleared its twiist Automated Insulin Delivery (AID) System for adults 18 and older with insulin-treated type 2 diabetes. The company estimates that adds about 5.5 million U.S. adults who manage type 2 with insulin. twiist launched nationally for type 1 in March 2026. It’s a prescription device, available through pharmacies in the U.S. only. Sequel says prescribing can begin immediately. The clearance rests on a pivotal trial published in Diabetes Care : 307 adults at 30 U.S. sites, followed for 13 weeks. Mean A1c went from 8.1% down 0.7 points. People who started at A1c of 9 or higher saw about a 2.1-point drop. Time in range (70 to 180 mg/dL) rose from 57% to 73%, about 3.8 more hours a day in range. Participants spent a median 95% of study time in AID mode. No severe hypoglycemia was reported in the study. Most people in the trial were pump-naive. Only 11% had prior carb-counting experience, 19% had used an AID system before, and just two entered already on a pump. People who had been on basal-bolus insulin used 19.3 fewer units per day on average while on twiist, per the study. They also kept modern type 2 meds on board: 56% were on a GLP-1, 37% on an SGLT-2, and 23% on both. Hardware basics from Sequel: a 300-unit cassette changed every three days, iiSure sensors for dose accuracy and faster blockage detection, and an algorithm based on Tidepool Loop. Compatible continuous glucose monitors named in the release include Abbott FreeStyle Libre 3 Plus and Senseonics Eversense 365. “For many adults living with type 2 diabetes, insulin therapy can feel like one more thing to manage in an already busy life,” Sequel CEO and co-founder Alan Lotvin, MD, said in the company release. Clinical commentary in the release came from Osama Hamdy, MD, PhD, of Joslin Diabetes Center. This is our analysis. AID has mostly served type 1. Opening the same style of pump to insulin-treated type 2 is a real access shift, especially for people who never counted carbs or wore a pump before. It’s also a pharmacy-channel play. That matters if your doctor and your local pharmacy are how you actually get care, not a specialty clinic. This is a prescription medical device, not a wellness gadget. Clearance expands an existing type 1 product. It is not a brand-new pump launch. The trial results above are from that pivotal study. Do not treat “no severe hypos in the study” as a guarantee for every user. Safety details live at twiist.com/safety. Talk to your clinician before changing how you take insulin. Type 2 on insulin has been waiting for the automated pump club to open the door. Sequel just did.
Brand information: Sequel Med Tech (GlobeNewswire)
Share this story Copy link LinkedIn Email